ERISA Ledger · U.S. DOL EBSA Form 5500 (2024)

Asklepios Biopharmaceutical, INC.

Official 2024 U.S. DOL Form 5500 summary for Asklepios Biopharmaceutical, INC. (Asklepios Biopharmaceuticals, INC. 401(k) Plan · EIN 20-0267834 · PN 001): $33.46M net assets, 404 active participants, and $3.09 per $10,000 (3.09 bps).

Reported Form 5500 Fee & Service Summary

Plan SponsorAsklepios Biopharmaceutical, INC.
Filing IdentifierAsklepios Biopharmaceuticals, INC. 401(k) Plan · EIN 20-0267834 · PN 001
Plan Category & State401(k) Defined Contribution (NC)
Asset-Size Peer Cohort$25M-$100M
Plan Net Assets (2024)$33.46M
Active Participants404
Direct Admin Fee Rate$3.09 per $10,000 (3.09 bps)
Cohort Peer Median$19.23 per $10,000 (19.23 bps)
Primary Recordkeeper / ProviderFidelity Investments
Schedule H Line 4a RemittanceTimely Employer Remittance (0 reported on Line 4a)

Browse all 78,373 plans & Schedule C vendors · Methodology · Meru AI